Literature DB >> 3293081

Observations on the role of endotoxin in graft-versus-host disease.

I A Lampert1, R H Moore, R Huby, J Cohen.   

Abstract

We have used a conventional murine model of bone marrow transplantation (BMT) to make a detailed study of the histological features of graft-versus-host disease (GvHD), and to study the effects of oral antibiotic decontamination of the gut flora. Comparison of the histological appearances of the small and large bowel indicated that the features of the GvHD were more severe in the large bowel. Bowel sterilisation caused a striking reduction in the severity of GvHD, both in the gut and at a distant site (the skin of the ear). The different effects of GvHD in the large as compared to the small bowel suggested that a factor was operative locally, and the effect of sterilisation linked this to the bacteria in the bowel. The fact that sites remote from the bowel were also affected suggested that a diffusible factor from the bowel produced by the bacteria of the gut was responsible. Studies elsewhere have suggested that the factor involved is likely to be endotoxin. In these experiments however it was evident that systemic administration of endotoxin did not aggravate the disease process and that in some instances the reverse was obtained. If therefore endotoxin is important the dose and its mode of its administration are likely to be critical.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293081

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  9 in total

Review 1.  The gut microbiota and graft-versus-host disease.

Authors:  David N Fredricks
Journal:  J Clin Invest       Date:  2019-05-01       Impact factor: 14.808

2.  Sequential measurement of the murine acute-phase protein serum amyloid P component (SAP) as an indicator of graft-versus-host disease following allogeneic bone marrow transplantation in mice.

Authors:  K F Bayston; R Huby; J Cohen
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

3.  Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.

Authors:  Yun Lin; Li Zhang; Ann X Cai; Mark Lee; Wandi Zhang; Donna Neuberg; Christine M Canning; Robert J Soiffer; Edwin P Alyea; Jerome Ritz; Nir Hacohen; Terry K Means; Catherine J Wu
Journal:  J Clin Invest       Date:  2011-03-14       Impact factor: 14.808

4.  The role of bacteria and pattern recognition receptors in GVHD.

Authors:  E Holler; K Landfried; J Meier; M Hausmann; G Rogler
Journal:  Int J Inflam       Date:  2010-10-31

5.  Complete suppression of the gut microbiome prevents acute graft-versus-host disease following allogeneic bone marrow transplantation.

Authors:  Jaak M Vossen; Harry F L Guiot; Arjan C Lankester; Ann C T M Vossen; Robbert G M Bredius; Ron Wolterbeek; Hanny D J Bakker; Peter J Heidt
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

Review 6.  Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure.

Authors:  Mireia Uribe-Herranz; Nela Klein-González; Luis Gerardo Rodríguez-Lobato; Manel Juan; Carlos Fernández de Larrea
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

Review 7.  Interplay Between the Intestinal Microbiota and Acute Graft-Versus-Host Disease: Experimental Evidence and Clinical Significance.

Authors:  Tao Hong; Rui Wang; Xiaoqi Wang; Shijie Yang; Weihao Wang; Qiangguo Gao; Xi Zhang
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 7.561

Review 8.  The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation.

Authors:  Simon Heidegger; Marcel R M van den Brink; Tobias Haas; Hendrik Poeck
Journal:  Front Immunol       Date:  2014-07-18       Impact factor: 7.561

Review 9.  Microbiota-Dependent Effects of IL-22.

Authors:  Morsal Sabihi; Marius Böttcher; Penelope Pelczar; Samuel Huber
Journal:  Cells       Date:  2020-09-29       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.